Patents by Inventor Susan K. Paulson

Susan K. Paulson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
    Publication number: 20220010005
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: February 16, 2021
    Publication date: January 13, 2022
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS
    Publication number: 20210347875
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 11, 2021
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
    Publication number: 20190211093
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 11, 2019
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS
    Publication number: 20190055308
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 8, 2018
    Publication date: February 21, 2019
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • METHODS FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS
    Publication number: 20180110854
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: June 5, 2017
    Publication date: April 26, 2018
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods for treating juvenile idiopathic arthritis
    Patent number: 9669093
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 6, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS
    Publication number: 20170044249
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: June 19, 2015
    Publication date: February 16, 2017
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K Paulson, Joanna Z. Peng
  • Methods for Treating Juvenile Idiopathic Arthritis
    Publication number: 20160151488
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 2, 2016
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods for treating juvenile idiopathic arthritis
    Patent number: 9284370
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: March 15, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods for Treating Juvenile Idiopathic Arthritis
    Publication number: 20160060336
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Application
    Filed: April 6, 2015
    Publication date: March 3, 2016
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY FORMULATION
    Publication number: 20160017030
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 21, 2016
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Methods for treating psoriasis by administering an antibody which binds an epitope of the p40 subunit of IL-12 and/or IL-23
    Patent number: 9051368
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: June 9, 2015
    Assignee: AbbVie, Inc.
    Inventors: Elliot Keith Chartash, William T. Barchuk, Susan K. Paulson, Joaquin M. Valdes, Alexandra B. Kimball
  • Methods for treating juvenile idiopathic arthritis by inhibition of TNF?
    Patent number: 8999337
    Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: April 7, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
  • Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
    Patent number: 8945545
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: February 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Joaquin Mario Valdes, Susan K. Paulson
  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY FORMULATIONS
    Publication number: 20140377275
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 25, 2014
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • HUMAN ANTIBODIES THAT BIND THE P40 SUBUNIT OF HUMAN IL-12/IL-23 AND USES THEREFOR
    Publication number: 20140093516
    Abstract: The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 3, 2014
    Inventors: Matthew Hruska, Susan K. Paulson, Peter Noertersheuser, Sven Mensing, Walid Awni
  • METHODS FOR TREATING PSORIASIS
    Publication number: 20140079714
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 20, 2014
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Thomas C. Harris, Martin Kaul, Parvez M. Mulani, Peter A. Noertersheuser, Martin M. Okun
  • Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
    Patent number: 8557239
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 15, 2013
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Tom C. Harris, Martin Kaul, Parvez M. Mulani, Peter Noertersheuser, Martin M. Okun
  • Multiple-variable dose regimen for treating TNFa-related disorders
    Publication number: 20130122011
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2012
    Publication date: May 16, 2013
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
    Publication number: 20120263731
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: November 11, 2011
    Publication date: October 18, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Wolfgang Fraunhofer, Laura Redden, Susan K. Paulson, Tong Zhu, Michael Neu, Markus Tschoepe, Carsten Weber, Martin Gastens, Alexander Feick